Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength? [Yahoo! Finance]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 7.7% gain over the past four weeks. The price rise can be attributed to growing investor optimism related to the strong uptake of the company's lead product, Galafold and the combination drug, Pombiliti + Opfolda. In the first six months of 2025, Galafold generated sales worth $233.1 million, which increased around 11% on a year-over-year basis. In the first six months of 2025, Pombiliti + Opfolda generated sales worth $46.8 million, up around 74% on a year-over-year basis. This pharmaceutical company is expected to post quarterly earnings of $0.12 per share in its upcoming report, which represents a year-over-year change of +20%. Revenues are expected to be $165 million, up 16.6% from the year-ago quarter. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong corre
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- Assessing Amicus Therapeutics (FOLD) Valuation as Shares Gain 11% Over Past Month [Yahoo! Finance]Yahoo! Finance
- How Strong Galafold and Pombiliti Sales Helped Amicus Therapeutics (FOLD) Surpass Expectations and Shift Its Outlook [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics (NASDAQ:FOLD) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Amicus Therapeutics (NASDAQ:FOLD) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Amicus Therapeutics: Moving Towards Consistent Profitability [Seeking Alpha]Seeking Alpha
FOLD
Earnings
- 11/4/25 - Beat
FOLD
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 12/3/25 - Form SCHEDULE
- FOLD's page on the SEC website